Drug Approval Drug Approval Process Tobacco Products Vaccine Approval Drug Safety Tobacco Control Food Safety Oversight Public Health Food Safety Regulations Medical Device Approval Vaccine Approval Process E-Cigarettes Consumer Protection Food Safety Advisory Committees Vaping Products Warning Sunscreen Approval Public Health Policy Cosmetic Regulations Manufacturing Standards Food Regulations Consumer Safety E-cigarettes Recalls Clinical Trials Cosmetic Safety Food and Drug Administration Import Restrictions Black Box Warning Product Warning Consent Decree Allergen Thresholds Food Safety Modernization Act (FSMA) USDA Mifepristone Recall Notice Advisory Committee Product Labeling Clinical Holds Healthcare Policy Food Safety Standards Food Safety Policies Food Additives Health Recommendations E-Cigarette Regulation E-cigarette Regulation Guidelines Import Alerts Health Policy Recommendations Kratom Products Drug Facility Oversight Cosmetics Drug Production Biologics License Application Biologics Evaluation Drug Advertising Nonprescription Drugs Drug Labeling Drug Recalls Sunscreen Regulation Vaccine Oversight Food Dyes Drug Enforcement Drug Promotion Genetic Therapy Regulations Biologics Evaluation and Research Public Meetings Peptides Pharmaceuticals Drug Approval Processes Product Safety Psychedelic Treatments Warnings Advisory Meeting Product Recall Product Authorization E-cigarette Authorization Drug Shortages Flavored Vaping Products Tobacco Regulation Drug Classification Dietary Supplement Regulation Tobacco Regulations Hearing Aids Substance Control FDA Inspections Warning Letters E-cigarette Policy Biologic License Application Biologics Public Policy Food Regulation Medical Approval Product Oversight Health Regulations Policy Changes Recall Animal Drugs
A May 22 deadline gives investors a window to seek lead-plaintiff status in the Central District of California case.
